+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2020

  • ID: 5130276
  • Drug Pipelines
  • June 2020
  • Region: Global
  • 42 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Diurnal Group Plc
  • Recordati SpA
  • Spruce Biosciences Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion - Pipeline Review, H1 2020, provides an overview of the Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline landscape.

Cushing’s disease is a condition which results from hypersecretion of adrenocorticotropic hormone (ACTH) due to pituitary gland tumor. Symptoms include acne or skin infections, backache, mental changes (such as depression, anxiety, or changes in behavior), plethora, menstrual disorders and weight gain. Treatment includes radiation, chemotherapy, and use of certain hormone-inhibiting drugs.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pituitary ACTH Hypersecretion (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Metabolic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Diurnal Group Plc
  • Recordati SpA
  • Spruce Biosciences Inc
  • Introduction
  • Report Coverage
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Overview
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Companies Involved in Therapeutics Development
  • Crinetics Pharmaceuticals Inc
  • Cyclacel Pharmaceuticals Inc
  • Diurnal Group Plc
  • Recordati SpA
  • Spruce Biosciences Inc
  • Strongbridge Biopharma plc
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Drug Profiles
  • Antisense RNAi Oligonucleotide to Inhibit Pro-Opiomelanocortin for ATCH-Dependent Cushing’s syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • osilodrostat phosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • seliciclib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Silibinin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing Disease and Congenital Adrenal Hyperplasia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tildacerfont - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • veldoreotide ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Crinetics Pharmaceuticals Inc, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Diurnal Group Plc, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Recordati SpA, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Spruce Biosciences Inc, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Strongbridge Biopharma plc, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
  • Crinetics Pharmaceuticals Inc
  • Cyclacel Pharmaceuticals Inc
  • Diurnal Group Plc
  • Recordati SpA
  • Spruce Biosciences Inc
  • Strongbridge Biopharma plc
Note: Product cover images may vary from those shown
Adroll
adroll